Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
NASDAQ:ONCE
Delisted

Spark Therapeutics Stock Price (Quote)

$113.57
+0 (+0%)
At Close: Jan 24, 2020

Range Low Price High Price Comment
30 days $113.57 $113.57 Friday, 24th Jan 2020 ONCE stock ended at $113.57. During the day the stock fluctuated 0% from a day low at $113.57 to a day high of $113.57.
90 days $108.00 $113.90
52 weeks $40.64 $114.20

Historical Spark Therapeutics prices

Date Open High Low Close Volume
May 15, 2019 $109.05 $109.19 $108.45 $108.50 371 319
May 14, 2019 $108.25 $109.19 $108.00 $109.03 494 519
May 13, 2019 $109.30 $109.83 $108.87 $109.51 237 051
May 10, 2019 $109.44 $109.92 $109.25 $109.79 246 037
May 09, 2019 $109.10 $110.12 $108.88 $109.80 304 973
May 08, 2019 $109.10 $109.52 $108.66 $109.51 153 431
May 07, 2019 $108.63 $109.44 $108.28 $109.38 312 439
May 06, 2019 $107.41 $109.50 $107.41 $109.33 364 482
May 03, 2019 $107.09 $108.11 $106.50 $108.03 941 761
May 02, 2019 $106.10 $107.00 $106.10 $107.00 311 005
May 01, 2019 $107.00 $107.85 $105.90 $106.05 822 259
Apr 30, 2019 $107.02 $107.02 $106.47 $106.69 447 435
Apr 29, 2019 $108.11 $108.27 $106.96 $107.01 338 626
Apr 26, 2019 $109.20 $109.39 $107.47 $107.87 1 598 385
Apr 25, 2019 $110.61 $111.43 $110.49 $111.38 510 053
Apr 24, 2019 $110.70 $110.89 $110.32 $110.67 451 849
Apr 23, 2019 $110.67 $110.86 $110.30 $110.60 582 906
Apr 22, 2019 $110.59 $111.35 $110.25 $110.60 436 954
Apr 18, 2019 $110.70 $110.95 $109.86 $110.62 1 237 597
Apr 17, 2019 $111.09 $111.09 $110.40 $110.71 878 715
Apr 16, 2019 $111.48 $111.50 $110.81 $110.85 506 536
Apr 15, 2019 $111.29 $111.52 $110.98 $111.18 661 906
Apr 12, 2019 $111.99 $112.16 $111.05 $111.12 949 372
Apr 11, 2019 $112.98 $112.98 $110.89 $111.74 2 055 460
Apr 10, 2019 $112.74 $112.88 $112.66 $112.88 859 257
Click to get the best stock tips daily for free!

About Spark Therapeutics

Spark Therapeutics Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company develops SPK-RPE65, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia... ONCE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT